
This article by Natasha Sumner was originally published on Microdose and appears here with permission.
A growing body of research into the therapeutic use of psychedelics, including — MDMA, psilocybin, LSD, ketamine, and DMT, are delivering promising results to treat a wide range of conditions such as post-traumatic stress disorder (PTSD), depression, end-of-life anxiety, eating disorders, stroke, and chronic pain. Robin Carhart-Harris, head of the Centre for Psychedelic Research at Imperial College London, wrote for The Guardian, “we can no longer ignore the potential of psychedelic drugs…psychedelics appear to increase brain ‘plasticity,’ which, broadly speaking, implies an accelerated ability to change.”